MTOR and nonpapillary renal cell carcinoma: Although the rapid development of targeted therapy and immunotherapies brings new hope to the treatment of ccRCC, these therapies still do not achieve optimal therapeutic results in ccRCC, due to the limited available molecular targets (tyrosine kinase and mTOR signaling pathways), drug resistance, immune suppression, and tumor heterogeneity [6–9].